文献速递免疫规划卫生政策与健康促进

韩国儿童人群20价肺炎球菌结合疫苗的成本效果分析

Cost-effectiveness analysis of the 20-valent pneumococcal conjugate vaccine for the pediatric population in South Korea.
PubMed 文献 · Vaccine · 2024-06-05

本研究在韩国四剂疫苗接种覆盖率超过97%的背景下,构建10年Markov模型,比较20价肺炎球菌结合疫苗(PCV20)与13价肺炎球菌结合疫苗(PCV13)在儿童人群中的成本效果。结果显示,PCV20较PCV13多获得74,855质量调整生命年(QALY),且总医疗费用少支出275,136,631美元,PCV20相对于PCV13为优势方案。

要点

  • 在总人群(n=51,431,305)中,PCV20较PCV13多获得74,855 QALY。
  • PCV20组较PCV13组总医疗费用少支出275,136,631美元。
  • PCV20因QALY更高且总医疗费用更低,相对于PCV13为优势方案。

核心结论

  • 在韩国人群中,PCV20相对于PCV13是具有成本效果且为优势方案的选择。

研究设计与样本

  • 构建Markov模型,计算10年内的成本和质量调整生命年(QALY)。
  • 健康状态包括易感状态、疾病状态(脑膜炎、菌血症、肺炎、急性中耳炎等侵袭性肺炎球菌疾病)和归因于肺炎球菌病的死亡。
  • 基于PCV13和PCV20覆盖的血清型、疫苗覆盖率、疫苗效力和人口规模估算肺炎球菌病的年发病率和死亡率。
  • 模型纳入疫苗、接种和疾病成本。

主要发现

  • 在总人群(n=51,431,305)中,PCV20较PCV13预防更多肺炎球菌病和死亡,多获得74,855 QALY。
  • PCV20组较PCV13组总医疗费用少支出275,136,631美元。
  • PCV20获得更多QALY且总医疗费用更低,为优势方案。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the cost-effectiveness of the 20-valent pneumococcal conjugate vaccine (PCV20) compared to 13-valent pneumococcal conjugate vaccine (PCV13) for the pediatric population in Korea, where the four-dose vaccine coverage rate is over 97%. METHODS: We constructed a Markov model to calculate the cost and quality-adjusted life-years (QALYs) over 10 years. The health states were susceptible states; disease states, which included invasive pneumococcal diseases such as meningitis, bacteremia, pneumonia, and acute otitis media; and death attributable to pneumococcal disease. The annual incidence and mortality due to pneumococcal diseases were estimated based on the serotypes covered by PCV13 and PCV20, vaccine coverage rate, vaccine effectiveness, and population size. Vaccine, administration, and disease costs were included in the model. RESULTS: In the total population (n = 51,431,305), PCV20 prevented more pneumococcal diseases and deaths, resulting in a gain of 74,855 QALY over PCV13. Meanwhile, the PCV20 group spent $275,136,631 less than the PCV13 group. As PCV20 gained more QALYs but spent less on total medical costs than PCV13, PCV20 was dominant over PCV13. CONCLUSIONS: In the Korean population, PCV20 is a cost-effective and dominant option over PCV13. Our findings provide evidence for decision-making regarding the introduction of PCV20 in countries with high vaccine coverage.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Kang DW, June Choe Y, Lee JY, et al. Cost-effectiveness analysis of the 20-valent pneumococcal conjugate vaccine for the pediatric population in South Korea. Vaccine. 2024. PMID: 38845302. doi:10.1016/j.vaccine.2024.05.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。